Evogene Ltd.

Regulatory Filings • Sep 17, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2020

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1A Slide Presentation: Canonic Ltd. Investor Presentation –September 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 17, 2020

EVOGENE LTD. (Registrant)

By: /s/ Dorit Kreiner

——————————————

Dorit Kreiner Chief Financial Officer EXHIBIT INDEX

EX	DE
HIB	SC
IT	RIP
NO	TIO
	N
99. 1	A S lide Pr tion : C nic Lt d. I r P atio Sep ber 20 20. nta sto ent tem ese ano nve res n –

Exhibit 99.1

Forward Looking Statement

This presentation contains "forward-looking statements, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating or other matters regarding or affecting Evogene Ltd. or its subsidiaries, induding Canonic Ltd. ("Subsidian" or "Company") (collectively, "Evogene" on "we"), that are coloring statements" as defined in the U.S. Private Securites Litigation Reform Act of 1995 (the "PSIR") and other securities laws. Such forward-looking statements may be identified by the use of such ","should", "banned", "intend" , "intend" and "potential" or word is using forvard-looking statements in this presentation when it discusses its near-tem value drivers, including statements to the it will reach commercialization, its short-term milestones and commercal milestones. For these statements, Evogene and Subscion of the safe harbor for forward-looking statements contained in the PSLR and other securities laws.

Such statements are based on current expections and assumptons, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantes Therefore, actual future results, performance or achievenents, and trends in the future of Subsidian and Evogene may differ materially from what is expressed or implied by such for a variety of factors, many of which are beyond Subsidiary s and Evogenes without imitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and fumishes with the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

All wirten and oral forward-looking statements atting on our behalf are expressy qualified in their entirety by the previous statements. Except for any obligations to disclose information as requires laws Subsidiary and Evogene disclaim any obligation or commitment o update any information contained in this presentation or to publicy release the results to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospects or other of form part of any invitation or offer to sel, or any solicitation of any invitation or offer to purchase of Evogene or Subsidiany, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in contract, commitment or relating thereto or to the securities of Evogene or Subsidiary.

The trademarks included heren are the property of the ent are used for reference purposes only. Such use should not be construent of the products or services of Evogene or Subsidiary.

• 2 | All rights reserved to Canonic Ltd. © Canonic Ltd. © | All rights reserved to Canonic Ltd.

OUR VISION

Commercialize effective, precise and stable medical cannabis products for optimized therapeutic impact

INTRODUCTION

Company Overview

Founded in 2019 as a spinoff from Evogene Ltd (EVGN)	We aim to develop & commercialize medical cannabis products		We aim to bring products all the way to the market starting from genetics to reach patients
Our products under development are based on stable high yield plants with optimized therapeutic effects			Al -based computational platform seeks to empower our plant breeding pipeline
		Commercialization is expected in early 2022, up to 4 products in the following 3 years

---

Global Cannabis Market

Medical cannabis is >60% of the global market

(source: prohibition partners Nov 2019)

Market Challenges & The Opportunity

THE CHALLENGES

= 7 | All rights resered to Canonic Ltd. © Canonic Ltd. © Canadic ============================================================================================================

Canonic Technology Powered By Evogene's GeneRator AI

CUTTING EDGE AI DRIVEN COMPUTATIONAL GENOMIC POWER TO TACKLE INDUSTRY CHALLENGES

Cannabis Value Chain

FROM GENOMICS TO PRODUCT

Canonic in the Cannabis Value Chain

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain

One Stop Shop From Genomics to Medical Cannabis Products

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain

Product Families Under Development

---

MetaYield+

Stable enhancement of total plant compounds. Focus on agronomic and consumer traits.

Increased compounds per plant [e.g. Increased trichomes prevalence]

= 13 | All rights reserved to Canonic Ltd. © =

Increased compounds per area [e.g. Dwarf & early flowering]

Precise+

Stable enhancement of specific active compounds. Focus on therapeutic traits.

Medical indication focus [e.g. Pain & Inflammation]

Compound profile focus [e.g. CBG, CBC]

• CANONIC

MetaYield+ : First Commercial Product

Canonic expects to commercialize its first varieties during 2022

MetaYield+ : Second Commercial Product

Canonic expects to commercialize its first varieties during 2022

Introduction to Precise + Product Family

Medical indication focus

We generate pre-clinical data to guide our breeding program towards specific medical indications

= 16 | All rights reserved to Canonic Ltd. © ---------------------------------------------------------------------------------------------------------------------------------

Next Generation Products

Canonic is developing and validating its varieties in collaboration with leading research centers

End-to-End Technologies

Developing in Israel's top cannabis R&D facilities

= 19 | All rights reserved to Canonic Ltd. ©

• CANONIC -

Unique Proprietary Database

Re-engineering traditional Cannabis breeding- Computational Technology

Unique database	Computational genomics	High throughput plant breeding
>>>	Proprietary Comparative Genomics ATTTCCGCACAAGGATTAGT ATCGCTTCACATAGGAAGT Novel Genes & Markers (IP protected)	Computed phenotyping >>> Genetic markers assisted selection	>>>	MetaYield+ Precise+
21 All rights reserved to Canonic Ltd. ©	THC / CBD / CBG / Functional Cannabinoids patterns	Pre-Clinical trials	CANONI

Cutting-Edge Technology Addressing Market Challenges

Team

Team

Board of directors

Ofer Haviv Chairman of the board Evogene CEO and President

Raanan Cohen Business strategy Former CEO Koor industries

Dr. Yossi Tam Cannabinoid clinical research Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew university

Advisors

Dr. Yariv Brotman Plant metabolic pathways Ben Gurion University & Max Planck institute of Molecular Plant Physiology

Dorit Kreiner Finance Evogene CFO

• 25 | All rights reserved to Canonic Ltd. © =

Shai Leviatov
Plant breeding

Commercial varieties breeding for more than 30 years in top leading multinational seeds companies.

Adv. Itay Rosenferld Business strategy

Cannabis entrepreneur and former BOD member of Intelicanna (TLV:INTL)

Nirit Elyovich Marketing strategy

Senior marketing specialist with over 20 years of B2C experience in various markets

Short Term Milestones

2020

• · Conduct pre-clinical studies to support the development of Canonic's medical cannabis products.
• · Demonstrate yield improvement in cannabis lines under development.
• · Engagement with commercial partners for cultivation and production.

2021

• Pre-commercial activity with first cannabis variety towards commercialization in 2022.
• · Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.

= 26 | All rights reserved to Canonic Ltd. © =

-- CANONIC -

Anticipated Commercial Milestones (5y)

Summary

Canonic aims to develop and commercialize medical grade Cannabis through a revolutionary genomic approach	Initial commercialization expected in 2022
Exclusive access to Evogene's CPB technology platform	Infrastructure in place - from seed to sale
Commercial partners in place for cultivation and production (IL & EU)	Leading academic partnerships for unique variety development
All rights reserved to Canonic Ltd.	ANON